{"paper_id":"420991e8-b454-4330-ab9f-1200d35a8008","body_text":"References\nKrálíčková M, Laganà AS, Ghezzi F, Vetvicka V (2020) Endometriosis and risk of ovarian cancer: what do we know? Arch Gynecol Obstet 301(1):1–10\nLiu S, Gao S, Wang XY, Wang DB (2012) Expression of miR-126 and Crk in endometriosis: miR-126 may affect the progression of endometriosis by regulating Crk expression. Arch Gynecol Obstet 285(4):1065–1072\nZhang Y, Qin X, Jiang J, Zhao W (2020) MicroRNA-126 exerts antitumor functions in ovarian cancer by targeting EGFL7 and affecting epithelial-to-mesenchymal transition and ERK/MAPK signaling pathway. Oncol Lett 20(2):1327–1335\nGuo T, Yuan D, Lin M, Zhu D, Xu N, Wang J (2020) Aberrant expression of ADAM9 in ovarian cancer and its clinical significance. J Clin Lab Anal 34(4):e23136\nHua Y, Liang C, Miao C, Wang S, Su S, Shao P, Liu B, Bao M, Zhu J, Xu A, Zhang J, Li J, Wang Z (2018) MicroRNA-126 inhibits proliferation and metastasis in prostate cancer via regulation of ADAM9. Oncol Lett 15(6):9051–9060\nFunding\nThe authors have not disclosed any funding.\nAuthor information\nAuthors and Affiliations\nContributions\nAuthor contributions\nMormile Raffaella Protocol/project development. Mormile Raffaella Data collection or management. Mormile Raffaella Data analysis. Mormile Raffaella Manuscript writing/editing.\nCorresponding author\nEthics declarations\nConflict of interests\nThe author declares no potential conflicts of interest.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nAbout this article\nCite this article\nMormile, R. Endometriosis and the risk of ovarian cancer: is miR126 the Achille’s heel?. Arch Gynecol Obstet 310, 1275–1276 (2024). https://doi.org/10.1007/s00404-024-07440-2\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-024-07440-2","source_license":"CC0","license_restricted":false}